Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia (CLARITY)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01363349 |
|
Recruitment Status :
Terminated
(pre-planned interim analysis of the Phase II/III CLARITY trial of BL-1020 indicate that the trial would not meet the pre-specified primary efficacy endpoint.)
First Posted : June 1, 2011
Results First Posted : September 18, 2014
Last Update Posted : September 18, 2014
|
Sponsor:
BioLineRx, Ltd.
Information provided by (Responsible Party):
BioLineRx, Ltd.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone. The primary efficacy endpoint will occur after 6 weeks of treatment; additional (secondary) efficacy endpoints will occur after 12 and 24 weeks of treatment.
Up to 450 patients will be randomized to CYP-1020 or risperidone in a 1:1 ratio. The study will utilize a flexible dose escalation scheme designed to allow patients to titrate to their maximally tolerated dose; doses of CYP-1020 may range from a minimum of 15 mg to a maximum of 35 mg, whereas doses of risperidone will range from a minimum of 1 mg to 3 mg BID (2-6 mg daily). To ensure effective blinding across all treatment groups, all patients will be treated twice daily with study drug and/or placebo, as indicated (i.e., double-dummy design).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Schizophrenia Cognitive Effect on Schizophrenic Patients | Drug: CYP-1020 Drug: Risperidone | Phase 2 Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 269 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia |
| Study Start Date : | May 2011 |
| Actual Primary Completion Date : | March 2013 |
| Actual Study Completion Date : | April 2013 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Schizophrenia
MedlinePlus related topics:
Schizophrenia
Drug Information available for:
Risperidone
| Arm | Intervention/treatment |
|---|---|
|
Experimental: CYP-1020
Dose titration 15-35mg/day for 6 months
|
Drug: CYP-1020
CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
Other Name: BL-1020 |
|
Active Comparator: Risperidone
Dose titration 2-6mg/day for 6 months
|
Drug: Risperidone |
Primary Outcome Measures :
- Cognition [ Time Frame: Baseline and 6 weeks ]To evaluate the cognitive benefits of treatment with CYP-1020 (formerly known as BL-1020) compared to risperidone after 6 weeks of treatment in patients experiencing acute exacerbation of schizophrenia. Assessed by calculating difference between CYP-1020 and Risperidone on mean change from baseline to Week 6 endpoint on MATRICS Consensus Cognition Battery (MCCB) normative composite score. MCCB is a neuropsychological test battery that comprises 10 measures of 7 different cognitive areas including speed of processing, verbal learning, memory-verbal and non verbal reasoning and problem solving, visual learning, social cognition, attention/vigilance.The study was terminated after the interim analysis. MCBB total score ranges from -50 to 150. Change from Baseline by Visit (LOCF)Higher score means better cognitive functioning.
Secondary Outcome Measures :
- Long Term Cognition [ Time Frame: 12 and 24 weeks of treatment ]Evaluation of the cognitive benefits of treatment with BL-1020 compared to risperidone after 12 and 24 weeks of treatment
- Long Term Schizophrenia Treatment [ Time Frame: Baseline and 6, 12 and 24 weeks of treatment ]Evaluation of the antipsychotic efficacy of BL-1020 compared to risperidone after 6, 12 and 24 weeks of treatment
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or non-pregnant or lactating female, 18-50 years of age inclusive
- Patients must have exhibited symptoms meeting the criteria of schizophrenia for at least one year, but not more than 20 years, prior to Screening
- Recent onset (not more than 30 days) of worsening of psychiatric symptoms at Screening.
-
Currently experiencing an acute exacerbation of schizophrenia, as defined by the following results at Screening and Baseline:
- ≥70 total score on the PANSS
- ≥4 (moderate) on two of the following four PANSS items: (1) delusions, (2) hallucinatory behaviors, (3) conceptual disorganization or (4) suspiciousness/persecution, where at least one of the two items must be either delusions or hallucinatory behaviors
- CGI-S score between 4 and 6 (moderately ill to severely ill) at the Screening and Baseline visits.
- Has exhibited a sufficient clinical response to at least one previous course of an anti-psychotic agent prescribed at a generally recognized therapeutic dose.
- Must have completed at least 5 years of formal education or its equivalent
Exclusion Criteria:
- Breastfeeding or pregnant
- Symptoms of schizophrenia for more than 20 years at the time of screening.
- Psychotic symptoms that have failed to improve (based on Investigator's opinion or documented medical history) following sufficient treatment with therapeutic doses of two or more anti-psychotics agents over the preceding 2 years
- Prior history of neuroleptic malignant syndrome
- Prior history or current evidence of moderate or severe tardive dyskinesia (mild is acceptable).
- Abnormal ECG evaluation
- History of confirmed epilepsy or prior seizure disorder (history of a single febrile seizure is not exclusionary)
- In the opinion of the investigator, unstable medical disease (e.g., malignancy, poorly controlled diabetes or hypertension, ischemic cardiac disease, dilated cardiomyopathy or valvular heart disease, pulmonary disease, liver disease, kidney disease)
- Acute infectious disease (e.g., malaria, dengue fever, hepatitis A), or chronic infectious disease (e.g., history of AIDS or HIV positivity, tuberculosis)
- Likely allergy, sensitivity or intolerance to BL-1020, perphenazine, risperidone, paliperidone, or any of the drug product excipients
- Any suicide attempt within the preceding 2 years
- Any Substance Dependence disorder
- High likelihood of substance abuse
- Diagnosis with one of the following DSM-IV-TR Axis I diagnoses: schizophreniform disorder, schizoaffective disorder, bipolar disorder, substance dependency, mood disorder with psychotic features; psychotic disorder NOS
- Requiring chronic treatment with benzodiazepines
- Requiring chronic treatment with mood stabilizers
- Previously treated with clozapine within 6 months prior to screening
- Any abnormal clinical laboratory test result that is judged by the Investigator to be clinically significant
- History of, or serologic evidence of, acute or chronic active hepatitis B or C
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01363349
Locations
Show 39 study locations
Sponsors and Collaborators
BioLineRx, Ltd.
Investigators
| Study Chair: | Arnon Aharon, MD | BioLineRx, Ltd. |
| Responsible Party: | BioLineRx, Ltd. |
| ClinicalTrials.gov Identifier: | NCT01363349 |
| Obsolete Identifiers: | NCT01365299 |
| Other Study ID Numbers: |
1020-CLIN-201 |
| First Posted: | June 1, 2011 Key Record Dates |
| Results First Posted: | September 18, 2014 |
| Last Update Posted: | September 18, 2014 |
| Last Verified: | September 2014 |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia Spectrum and Other Psychotic Disorders Mental Disorders Risperidone Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Physiological Effects of Drugs Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Dopamine Antagonists Dopamine Agents |